J&J, Merck autoimmune news

In an SEC filing, Merck said that an arbitration hearing will take place later this month to settle a dispute related to a 1998 deal between Johnson & Johnson's Centocor Ortho Biotech Inc. subsidiary and Schering-Plough Corp. for autoimmune drugs Remicade infliximab and Simponi golimumab. Centocor is seeking a return of marketing rights to the drugs, alleging that Schering-Plough's 2009 merger with Merck constitutes a change of control. Merck and Schering-Plough said they believe the merger does not give JNJ the right to terminate the deal. ...